This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Nearly 13,000 Patients Have Benefited From IMRIS VISIUS IMRI

2014 procedures expected to increase 31% over 8-year total as intraoperative MRI utilization expands to improve outcomes in growing number of neurosurgical applications

MINNEAPOLIS, Jan. 8, 2014 /PRNewswire/ - IMRIS Inc. (NASDAQ: IMRS) (TSX: IM) ("IMRIS" or the "Company") today announced that an internal study of 40 worldwide VISIUS ® Surgical Theatre hospital customers indicates that nearly 13,000 patients have been treated using intraoperative MRI (iMRI) since the first installation in 2005. Four of 27 US hospitals - located in Boston, MA; St. Louis, MO; and Minneapolis and St. Paul, MN - currently using VISIUS iMRI are approaching 1,000 cases performed.

Dr. Frederick Boop, Co-director of the Le Bonheur Neuroscience Institute in Memphis, TN, credits VISIUS iMRI with reducing reoperation rates. "Intraoperative MRI is an important tool in our pediatric program by allowing us to get a more complete removal of these tumors and better overall visualization without moving the patient and knowing we won't have to bring the patient back for another operation," he said.

With more installations coming online and procedure numbers growing steadily, IMRIS President and CEO Jay D. Miller said the company estimates the volume will be almost 17,000 by the end of 2014, an increase of roughly 31% in one year over the previous eight years. "With increasing adoption and utilization, more neurosurgeons and hospitals are recognizing the decision support advantage of enhanced visualization in the intraoperative setting and reduced risks associated with not moving patients for imaging," he said.

"The top neurosurgical hospitals are making the IMRIS solution their standard of care and not only increasing the number of procedures completed in the suite," Miller added, "but also expanding the types of applications and conditions other than various brain tumors, such as epilepsy, Parkinson's disease, stroke intervention, aneurysm, and Chiari malformation, and other neurological procedures using deep brain stimulation, ablation and other technologies with iMR. Also, the recent addition of VISIUS iCT expands our solution into spinal conditions, trauma and intricate reconstructions."

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,619.51 +23.16 0.13%
S&P 500 2,063.12 +5.48 0.27%
NASDAQ 4,986.8670 +28.3990 0.57%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs